サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1784072

希少疾患の臨床試験の世界市場

Rare Disease Clinical Trials

出版日
ページ情報
英文 183 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
希少疾患の臨床試験の世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

希少疾患の臨床試験の世界市場は2030年までに197億米ドルに達する見込み

2024年に140億米ドルと推定される希少疾患の臨床試験の世界市場は、2024年から2030年にかけてCAGR 5.9%で成長し、2030年には197億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるフェーズiは、CAGR7.5%を記録し、分析期間終了までに86億米ドルに達すると予測されます。フェーズIIセグメントの成長率は、分析期間中CAGR 4.3%と推定されます。

米国市場は37億米ドルと推定、中国はCAGR 5.7％で成長予測

米国の希少疾患の臨床試験市場は、2024年に37億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに32億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.7%と4.8%と予測されています。欧州では、ドイツがCAGR 4.5%で成長すると予測されています。

世界の希少疾患の臨床試験市場- 主要動向と促進要因のまとめ

希少疾患の臨床試験が医薬品開発で重要性を増している理由とは？

製薬企業や規制当局が希少疾患や希少疾病に苦しむ患者のアンメット・メディカル・ニーズに対応する取り組みを強化しているため、希少疾患の臨床試験は医薬品開発における焦点となっています。7,000を超える希少疾病が確認され、世界中で数百万人が罹患しており、有効な治療法に対する需要は飛躍的に高まっています。従来の医薬品開発モデルでは、患者数が限られ、研究コストが高いため、希少疾患は見過ごされがちでしたが、ゲノミクス、標的治療、規制面でのインセンティブの進歩により、状況は一変しました。政府や医療機関は、希少疾患治療薬の開発を奨励するため、助成金、税額控除、早期承認経路を提供しています。適応試験デザイン、患者中心のアプローチ、分散型臨床試験の採用が増加し、希少疾患の研究実施の可能性がさらに向上しています。新規治療に対するニーズが高まるにつれ、希少疾患の臨床試験はバイオ医薬品のイノベーションに不可欠な要素となってきています。

新しいテクノロジーは、希少疾患の臨床試験をどのように向上させているのでしょうか？

技術の進歩は、希少疾患の臨床試験の効率と成功率を大幅に向上させています。人工知能（AI）と機械学習は、遺伝子プロファイルと電子カルテ（EHR）に基づいて適格な参加者を特定することで、患者募集を合理化しています。リアルワールドデータ（RWD）とリアルワールドエビデンス（RWE）の利用は、研究者が疾患の進行と治療効果に関する洞察を得るのに役立ち、大規模な患者コホートへの依存を軽減しています。バーチャル臨床試験と遠隔患者モニタリングの採用により、特に地理的に分散している希少疾患患者にとって、臨床試験へのアクセス性が向上しています。バイオマーカー主導の医薬品開発と精密医療のアプローチも希少疾患研究を加速させ、より的を絞った効果的な治療戦略を可能にしています。さらに、遺伝子治療とCRISPRベースの技術は、画期的な希少疾患治療への道を開き、臨床試験の期間を短縮し、成功の可能性を高めています。

希少疾患臨床試験の拡大を促す市場動向とは？

希少疾病治療薬開発への注目の高まりと規制上の優遇措置が、希少疾病臨床試験市場を大きく後押ししています。FDAの希少疾病用医薬品法と欧州医薬品庁（EMA）の希少疾病指定プログラムは、市場独占権、手数料の減額、優先審査プログラムなどを提供することで、製薬会社が希少疾病研究に投資するインセンティブを与えています。患者支援団体の台頭や試験デザインへの患者の関与の増加により、試験の継続率や募集効率が向上しています。遺伝子・細胞治療研究の拡大により、希少遺伝性疾患、希少がん、神経変性疾患を対象とした臨床試験が急増しています。さらに、製薬会社、バイオテクノロジー企業、研究機関の戦略的提携が希少疾患治療薬開発のイノベーションを促進しています。世界の希少疾患登録とAIを活用した臨床試験プラットフォームの出現は、試験デザインとデータ分析をさらに強化し、希少疾患研究をより実行可能で影響力のあるものにしています。

希少疾患の臨床試験市場の主な成長促進要因は？

世界の希少疾患の臨床試験市場の成長は、規制当局の支援の増加、ゲノム医療の進歩、分散型臨床試験モデルの拡大など、いくつかの要因によってもたらされます。希少遺伝性疾患の罹患率の上昇と個別化治療の需要により、効率的で的を絞った臨床試験の必要性が高まっています。AI主導の分析、仮想患者モニタリング、実世界データの統合により、臨床試験プロセスの最適化、コスト削減、医薬品承認の迅速化が進んでいます。さらに、バイオ製薬企業は患者中心の調査手法を活用することで、希少疾病研究の成功を確実なものとするため、採用率と維持率を向上させています。希少疾病用医薬品開発への投資が拡大していることに加え、製薬企業と患者支援団体との協力体制が市場の拡大をさらに後押ししています。希少疾患研究が進化を続ける中、革新的な試験デザインと最先端のバイオテクノロジーが治療開発のブレークスルーを促し、世界中の患者の転帰を改善すると期待されています。

セグメント

フェーズ（第I相、第II相、第III相、第IV相）;治療領域（がん、心血管疾患、神経疾患、感染症、遺伝性疾患、自己免疫・炎症、血液疾患、筋骨格系疾患、その他の治療領域）;スポンサー（製薬・バイオテクノロジー企業、非営利団体、その他のスポンサー）

調査対象企業の例

  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Amgen Inc.
  • Arcturus Therapeutics
  • AstraZeneca
  • Biogen Inc.
  • Charles River Laboratories
  • Editas Medicine
  • F. Hoffmann-La Roche Ltd.
  • Fortrea
  • ICON plc
  • IQVIA Inc.
  • Labcorp Drug Development
  • Medpace
  • Novartis AG
  • Parexel International Corporation
  • Pfizer Inc.
  • Precision for Medicine
  • PTC Therapeutics
  • Sanofi
  • Scholar Rock
  • Takeda Pharmaceutical Company
  • Ultragenyx Pharmaceutical Inc.
  • United Therapeutics
  • Vertex Pharmaceuticals

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32759

Global Rare Disease Clinical Trials Market to Reach US$19.7 Billion by 2030

The global market for Rare Disease Clinical Trials estimated at US$14.0 Billion in the year 2024, is expected to reach US$19.7 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the Phase II segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 5.7% CAGR

The Rare Disease Clinical Trials market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.2 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Rare Disease Clinical Trials Market - Key Trends & Drivers Summarized

Why Are Rare Disease Clinical Trials Gaining Importance in Drug Development?

Rare disease clinical trials have become a focal point in drug development as pharmaceutical companies and regulatory agencies intensify efforts to address the unmet medical needs of patients suffering from rare and orphan diseases. With over 7,000 identified rare diseases affecting millions worldwide, the demand for effective therapies has grown exponentially. Traditional drug development models often overlook rare diseases due to limited patient populations and high research costs, but advancements in genomics, targeted therapies, and regulatory incentives have transformed the landscape. Governments and health organizations are providing grants, tax credits, and accelerated approval pathways to encourage rare disease drug development. The increasing adoption of adaptive trial designs, patient-centric approaches, and decentralized clinical trials has further improved the feasibility of conducting research on rare diseases. As the need for novel treatments rises, rare disease clinical trials are becoming an integral part of biopharmaceutical innovation.

How Are Emerging Technologies Improving Rare Disease Clinical Trials?

Technological advancements have significantly enhanced the efficiency and success rates of rare disease clinical trials. Artificial intelligence (AI) and machine learning are streamlining patient recruitment by identifying eligible participants based on genetic profiles and electronic health records (EHRs). The use of real-world data (RWD) and real-world evidence (RWE) is helping researchers gain insights into disease progression and treatment effectiveness, reducing the reliance on large patient cohorts. The adoption of virtual clinical trials and remote patient monitoring has improved trial accessibility, particularly for geographically dispersed rare disease patients. Biomarker-driven drug development and precision medicine approaches have also accelerated rare disease research, allowing for more targeted and effective treatment strategies. Additionally, gene therapy and CRISPR-based technologies are paving the way for groundbreaking rare disease treatments, reducing trial timelines and increasing the likelihood of successful outcomes.

What Market Trends Are Driving Rare Disease Clinical Trial Expansion?

The growing focus on orphan drug development and regulatory incentives has significantly boosted the rare disease clinical trial market. The FDA’s Orphan Drug Act and the European Medicines Agency’s (EMA) orphan designation program have incentivized pharmaceutical companies to invest in rare disease research by offering market exclusivity, reduced fees, and priority review programs. The rise of patient advocacy groups and increased patient engagement in trial designs have improved trial retention rates and recruitment efficiency. The expansion of gene and cell therapy research has led to a surge in clinical trials targeting rare genetic disorders, rare cancers, and neurodegenerative diseases. Additionally, strategic collaborations between pharmaceutical companies, biotech firms, and research institutions are driving innovation in rare disease drug development. The emergence of global rare disease registries and AI-powered clinical trial platforms is further enhancing trial design and data analysis, making rare disease research more viable and impactful.

What Are the Key Growth Drivers of the Rare Disease Clinical Trials Market?

The growth in the global rare disease clinical trials market is driven by several factors, including increasing regulatory support, advancements in genomic medicine, and the expansion of decentralized clinical trial models. The rising incidence of rare genetic disorders and the demand for personalized treatments have intensified the need for efficient and targeted clinical trials. The integration of AI-driven analytics, virtual patient monitoring, and real-world data is optimizing trial processes, reducing costs, and accelerating drug approvals. Additionally, biopharmaceutical companies are leveraging patient-centric trial methodologies to improve recruitment and retention rates, ensuring the success of rare disease studies. The growing investment in orphan drug development, coupled with collaborative efforts between pharmaceutical companies and patient advocacy groups, is further fueling market expansion. As rare disease research continues to evolve, innovative trial designs and cutting-edge biotechnologies are expected to drive breakthroughs in treatment development, improving outcomes for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Rare Disease Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase (Phase I, Phase II, Phase III, Phase IV); Therapeutic Area (Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases, Genetic Disorders, Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas); Sponsor (Pharma & Biotech Companies, Non-Profit Organizations, Other Sponsors)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Amgen Inc.
  • Arcturus Therapeutics
  • AstraZeneca
  • Biogen Inc.
  • Charles River Laboratories
  • Editas Medicine
  • F. Hoffmann-La Roche Ltd.
  • Fortrea
  • ICON plc
  • IQVIA Inc.
  • Labcorp Drug Development
  • Medpace
  • Novartis AG
  • Parexel International Corporation
  • Pfizer Inc.
  • Precision for Medicine
  • PTC Therapeutics
  • Sanofi
  • Scholar Rock
  • Takeda Pharmaceutical Company
  • Ultragenyx Pharmaceutical Inc.
  • United Therapeutics
  • Vertex Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Rare Disease Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increased Orphan Drug Development Pipelines Propel Demand for Rare Disease Clinical Trial Infrastructure
    • Rising Patient Advocacy and Engagement Strengthens Feasibility and Recruitment in Rare Disease Trials
    • Advancements in Genomic Profiling and Target Identification Accelerate Trial Design and Execution
    • Regulatory Incentives for Orphan Drugs Spur Investment in Rare Disease Research and Clinical Studies
    • Shift Toward Decentralized and Virtual Trials Throws the Spotlight on Remote Patient Monitoring Technologies
    • Emergence of Adaptive Trial Designs Enhances Efficiency and Drives Broader Application in Small Populations
    • Partnerships Between CROs and Biotech Firms Streamline Trial Operations and Improve Data Quality
    • Use of AI in Site Selection and Trial Matching Optimizes Outcomes and Reduces Time-to-Market
    • Expansion of Global Patient Registries Improves Access to Trial Candidates and Rare Cohorts
    • Growth in Gene Therapy and mRNA-Based Platforms Supports Expansion of Trial Modalities
    • Increased Funding by Non-Profits and Government Agencies Strengthens Clinical Trial Ecosystems
    • Real-World Evidence Integration in Trial Protocols Enhances Regulatory Submissions and Market Access
    • Regulatory Flexibility in Trial Requirements for Rare Indications Supports Innovative Study Designs
    • Patient-Centric Trial Models Propel Use of At-Home Sampling and Mobile Health Monitoring
    • Rise in Basket and Umbrella Trials for Rare Genetic Disorders Expands Protocol Scalability
    • Technological Advancements in EDC and eCOA Platforms Improve Data Collection in Remote Trials
    • Biomarker-Driven Stratification Enhances Endpoint Precision and Drives Early Phase Trial Success
    • Collaborative Consortia Among Academia, Pharma, and Regulators Bolster Rare Disease Trial Networks
    • Growth in Pediatric Rare Disease Studies Requires Age-Specific Protocol Adaptations and Ethical Oversight
    • Globalization of Trial Sites in Low-Prevalence Regions Expands Trial Reach and Accelerates Enrollment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rare Disease Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Rare Disease Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Autoimmune & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Autoimmune & Inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hematologic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Hematologic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Cardiovascular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Cardiovascular Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Non-Profit Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Non-Profit Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Other Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Other Sponsors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rare Disease Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 36: USA Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • CANADA
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • JAPAN
    • Rare Disease Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • CHINA
    • Rare Disease Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 54: China Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • EUROPE
    • Rare Disease Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Rare Disease Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • FRANCE
    • Rare Disease Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • GERMANY
    • Rare Disease Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 82: Italy Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Italy 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • UNITED KINGDOM
    • Rare Disease Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 88: UK Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: UK 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 90: UK Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: UK 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of Europe 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Rare Disease Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Asia-Pacific 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World 6-Year Perspective for Rare Disease Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 106: Rest of World Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Therapeutic Area - Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of World 6-Year Perspective for Rare Disease Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Autoimmune & Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas, Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases and Genetic Disorders for the Years 2025 & 2030
    • TABLE 108: Rest of World Recent Past, Current & Future Analysis for Rare Disease Clinical Trials by Sponsor - Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of World 6-Year Perspective for Rare Disease Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Non-Profit Organizations and Other Sponsors for the Years 2025 & 2030

IV. COMPETITION